• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.169.1-169.1
• /
• 2003

Recently development of cell-based assay systems which are useful in molecular cell biology and drug discovery attracts significant attention. Here, we introduce a new technologies for monitoring enzyme activity and its inhibition inside living cells. Among various enzymes, proteases are important targets for studying various biological and disease-related processes such as viral infections, apoptosis and Alzheimer's disease. In this study, a sensitive cell-based protease detection system that enables direct fluorescence detection of a target protease and its inhibition inside living cells is introduced. (omitted)

• Proceedings of the Korean Vacuum Society Conference
• /
• 2013.02a
• /
• pp.83-83
• /
• 2013

To date, various nanobiotechnologicalapproaches for biosensors and drug development have been explosively studied. Despite of successful demonstrations, the new technologies hardly enjoyed routine applications in practical nanobiomedicine. Here, researchers trained at the interface of basic sciences and engineering are expected to play critical roles. In this tutorial, I will introduce recent studies which harness graphene derivatives for developing bioanalytical platforms to quantitatively analyze various enzyme activities and biomarkers. The systems rely on attractive interaction between graphene oxide and nucleic acids or phospholipids. Recently, one of the graphene-based bioassay system was applied to anti-viral drug screening and potent hit compounds were identified to treat hepatitis C. This study clearly shows that a new nanobio-technology can be routinely implemented in drug discovery, providing many advantages over conventional methods.

• Proceedings of the Microbiological Society of Korea Conference
• /
• 2009.05a
• /
• pp.68-69
• /
• 2009

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.15
• /
• pp.6247-6251
• /
• 2014

Background: The aim of the present study was to investigate the involvement of emodin on the growth of human breast cancer MCF-7 and MDA-MB-231 cells and the estrogen (E2) signal pathway in vitro. Materials and Methods: MTT assays were used to detect the effects of emodin on E2 induced proliferation of MCF-7 and MDA-MB-231 cells. Flow cytometry (FCM) was applied to determine the effect of emodin on E2-induced apoptosis of MCF-7 cells. Western blotting allowed detection of the effects of emodin on the expression of estrogen receptor ${\alpha}$, cyclin D1 and B-cell lymphoma-2 (Bcl-2), mitogen-activated protein kinases (MAPK) and phosphatidylinostiol 3-kinases (PI3K). Luciferase assays were emplyed to assess transcriptional activity of $ER{\alpha}$. Results: Emodin could inhibit E2-induced MCF-7 cell proliferation and anti-apoptosis effects, and arrest the cell cycle in G0/G1 phase, further blocking the effect of E2 on expression and transcriptional activity of $ER{\alpha}$. Moreover, Emodin influenced the ER ${\alpha}$ genomic pathway via downregulation of cyclin D1 and Bcl-2 protein expression, and influenced the non-genomic pathway via decreased PI3K/Akt protein expression. Conclusions: These findings indicate that emodin exerts inhibitory effects on MCF-7 cell proliferation via inhibiting both non-genomic and genomic pathways.

• Bulletin of the Korean Chemical Society
• /
• v.31 no.7
• /
• pp.2039-2042
• /
• 2010

• Bulletin of the Korean Chemical Society
• /
• v.31 no.11
• /
• pp.3441-3444
• /
• 2010

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2003.10b
• /
• pp.84-85
• /
• 2003

The process of drug development has seen major changes over the last two decades with the movement away from standard small molecule drug discovery programs, through computer-assisted drug design methodologies towards biotechnologically derived products. The aim of duplication of endogenously active materials to be administered exogenously has enormous impact on development practices and evaluation of safety.(omitted)

• Journal of the Korea Institute of Information and Communication Engineering
• /
• v.25 no.12
• /
• pp.1797-1808
• /
• 2021

Artificial intelligence is considered one of the core technologies leading the 4th industrial revolution. It is adopted in various fields bringing about a huge paradigm shift throughout our society. The field of biotechnology is no exception. It is undergoing innovative development by converging with other disciplines such as computers, electricity, electronics, and so on. In drug discovery and development, big data-based AI technology has a great potential of improving the efficiency and quality of drug development, rapidly advancing to overcome the limitations in the existing drug development process. AI technology is to be specialized and developed for the purpose including clinical efficacy and safety-related end points based on the multidisciplinary knowledge such as biology, chemistry, toxicology, pharmacokinetics, etc. In this paper, we review the current status of AI technology applied for drug discovery and consider its limitations and future direction.

• Natural Product Sciences
• /
• v.28 no.3
• /
• pp.93-104
• /
• 2022

Methicillin-resistant Staphylococcus aureus (MRSA) is a serious threat to the global healthcare system. Ineffective and resistance to antibiotic treatments have increased morbidity and mortality rates worldwide. New and effective antibiotics are needed to combat against bacterial resistance. Endophytic fungi are crucial reservoirs of novel bioactive metabolites. In particular, the secondary metabolites show promising therapeutic potential, notably, antibacterial. This review discussed the emerging potential of endophytic fungi as anti-MRSA agents. The ecological sources of endophytic fungi were discussed with the synthesis of bioactive metabolites. The mode of antibacterial actions was elucidated to give a better understanding of the mechanisms involved. This review may serve as an important reference for future discovery and developments of anti-MRSA agents from endophytic fungi.

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2020.12a
• /
• pp.14-14
• /
• 2020

In December 2019, the COVID-19 epidemic was discovered in Wuhan, China, and since has disseminated around the world impacting human health for millions. Herein, in-silico drug discovery approaches were utilized to identify potential candidates as Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (M^pro) inhibitors. We investigated several databases including natural and natural-like products (>100,000 molecules), DrugBank database (10,036 drugs), major metabolites isolated from daily used spices (32 molecules), and current clinical drug candidates for the treatment of COVID-19 (18 drugs). All tested compounds were prepared and screened using molecular docking techniques. Based on the calculated docking scores, the top ones from each project under investigation were selected and subjected to molecular dynamics (MD) simulations followed by molecular mechanics-generalized Born surface area (MM-GBSA) binding energy calculations. Combined long MD simulations and MM-GBSA calculations revealed the potent compounds with prospective binding affinities against M^pro. Structural and energetic analyses over the simulated time demonstrated the high stabilities of the selected compounds. Our results showed that 4-bis([1,3]dioxolo)pyran-5-carboxamide derivatives (natural and natural-like products database), DB02388 and Cobicistat (DB09065) (DrugBank database), salvianolic acid A (spices secondary metabolites) and TMC-310911 (clinical-trial drugs database) exhibited high binding affinities with SARS-CoV-2 M^pro. In conclusion, these compounds are up-and-coming anti-COVID-19 drug candidates that warrant further detailed in vitro and in vivo experimental estimations.